195 related articles for article (PubMed ID: 30495974)
1. Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials.
Nunez DJ; Alexander M; Yerges-Armstrong L; Singh G; Byttebier G; Fabbrini E; Waterworth D; Meininger G; Galwey N; Wallentin L; White HD; Vannieuwenhuyse B; Alazawi W; Kendrick S; Sattar N; Ferrannini E
Am J Physiol Gastrointest Liver Physiol; 2019 Mar; 316(3):G372-G386. PubMed ID: 30495974
[TBL] [Abstract][Full Text] [Related]
2. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Buse JB; Klonoff DC; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Maggs DG; Wintle ME
Clin Ther; 2007 Jan; 29(1):139-53. PubMed ID: 17379054
[TBL] [Abstract][Full Text] [Related]
3. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity.
Newsome P; Francque S; Harrison S; Ratziu V; Van Gaal L; Calanna S; Hansen M; Linder M; Sanyal A
Aliment Pharmacol Ther; 2019 Jul; 50(2):193-203. PubMed ID: 31246368
[TBL] [Abstract][Full Text] [Related]
4. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.
Shao N; Kuang HY; Hao M; Gao XY; Lin WJ; Zou W
Diabetes Metab Res Rev; 2014 Sep; 30(6):521-9. PubMed ID: 24823873
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
Guo W; Tian W; Lin L; Xu X
Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
[TBL] [Abstract][Full Text] [Related]
6. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
Klonoff DC; Buse JB; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Wintle ME; Maggs DG
Curr Med Res Opin; 2008 Jan; 24(1):275-86. PubMed ID: 18053320
[TBL] [Abstract][Full Text] [Related]
7. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
Cusi K; Sattar N; García-Pérez LE; Pavo I; Yu M; Robertson KE; Karanikas CA; Haupt A
Diabet Med; 2018 Oct; 35(10):1434-1439. PubMed ID: 29869810
[TBL] [Abstract][Full Text] [Related]
8. The effect of enriched chicory inulin on liver enzymes, calcium homeostasis and hematological parameters in patients with type 2 diabetes mellitus: A randomized placebo-controlled trial.
Farhangi MA; Javid AZ; Dehghan P
Prim Care Diabetes; 2016 Aug; 10(4):265-71. PubMed ID: 26872721
[TBL] [Abstract][Full Text] [Related]
9. Differences among patients with and without nonalcoholic fatty liver disease having elevated alanine aminotransferase levels at various stages of metabolic syndrome.
Sogabe M; Okahisa T; Kurihara T; Takehara M; Kagemoto K; Okazaki J; Kida Y; Hirao A; Tanaka H; Tomonari T; Taniguchi T; Okamoto K; Nakasono M; Takayama T
PLoS One; 2020; 15(8):e0238388. PubMed ID: 32866186
[TBL] [Abstract][Full Text] [Related]
10. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.
Sattar N; Fitchett D; Hantel S; George JT; Zinman B
Diabetologia; 2018 Oct; 61(10):2155-2163. PubMed ID: 30066148
[TBL] [Abstract][Full Text] [Related]
11. Liver enzymes, type 2 diabetes, and metabolic syndrome in middle-aged, urban Chinese men.
Villegas R; Xiang YB; Elasy T; Cai Q; Xu W; Li H; Fazio S; Linton MF; Raiford D; Zheng W; Shu XO
Metab Syndr Relat Disord; 2011 Aug; 9(4):305-11. PubMed ID: 21495862
[TBL] [Abstract][Full Text] [Related]
12. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes.
Vozarova B; Stefan N; Lindsay RS; Saremi A; Pratley RE; Bogardus C; Tataranni PA
Diabetes; 2002 Jun; 51(6):1889-95. PubMed ID: 12031978
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis.
Lian J; Fu J
Front Endocrinol (Lausanne); 2021; 12():649018. PubMed ID: 33841337
[TBL] [Abstract][Full Text] [Related]
14. Insulin resistance is independently associated with liver aminotransferases in diabetic patients without ultrasound signs of nonalcoholic fatty liver disease.
Esteghamati A; Noshad S; Khalilzadeh O; Khalili M; Zandieh A; Nakhjavani M
Metab Syndr Relat Disord; 2011 Apr; 9(2):111-7. PubMed ID: 21091060
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and associated metabolic factors of fatty liver disease in the elderly.
Wang Z; Xu M; Peng J; Jiang L; Hu Z; Wang H; Zhou S; Zhou R; Hultström M; Lai EY
Exp Gerontol; 2013 Aug; 48(8):705-9. PubMed ID: 23721951
[TBL] [Abstract][Full Text] [Related]
16. The Symptoms of Gastroesophageal Reflux Disease Correlate with High Body Mass Index, the Aspartate Aminotransferase/Alanine Aminotransferase Ratio and Insulin Resistance in Japanese Patients with Non-alcoholic Fatty Liver Disease.
Fujiwara M; Eguchi Y; Fukumori N; Eguchi H; Tomonaga M; Yoshioka T; Hyakutake M; Sakanishi Y; Kyoraku I; Sugioka T; Fujimoto K; Kusano M; Yamashita S
Intern Med; 2015; 54(24):3099-104. PubMed ID: 26666594
[TBL] [Abstract][Full Text] [Related]
17. The effects of vitamin D supplementation on hepatic dysfunction, vitamin D status, and glycemic control in children and adolescents with vitamin D deficiency and either type 1 or type 2 diabetes mellitus.
Nwosu BU; Maranda L
PLoS One; 2014; 9(6):e99646. PubMed ID: 24918447
[TBL] [Abstract][Full Text] [Related]
18. Parental history of type 2 diabetes and cardiometabolic biomarkers in offspring.
Abbasi A; Corpeleijn E; van der Schouw YT; Stolk RP; Spijkerman A; van der A DL; Navis G; Bakker SJ; Beulens JW
Eur J Clin Invest; 2012 Sep; 42(9):974-82. PubMed ID: 22568410
[TBL] [Abstract][Full Text] [Related]
19. Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin.
Freemark M
Acta Paediatr; 2007 Sep; 96(9):1326-32. PubMed ID: 17718786
[TBL] [Abstract][Full Text] [Related]
20. Association between alanine aminotransferase as surrogate of fatty liver disease and physical activity and sedentary time in adolescents with obesity.
Julian V; Bergsten P; Ennequin G; Forslund A; Ahlstrom H; Ciba I; Dahlbom M; Furthner D; Gomahr J; Kullberg J; Maruszczak K; Morwald K; Olsson R; Pixner T; Schneider A; Pereira B; Ring-Dimitriou S; Thivel D; Weghuber D
Eur J Pediatr; 2022 Aug; 181(8):3119-3129. PubMed ID: 35771354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
